Viaderma Inc
ViaDerma, Inc., through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company's lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. It is also developing various products for vitiligo, psoriasis, eczema, and other skin conditions using SkinPass topical delivery system, as w… Read more
Viaderma Inc (VDRM) - Total Assets
Latest total assets as of September 2024: $4.07 Million USD
Based on the latest financial reports, Viaderma Inc (VDRM) holds total assets worth $4.07 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Viaderma Inc - Total Assets Trend (2007–2023)
This chart illustrates how Viaderma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Viaderma Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Viaderma Inc's total assets of $4.07 Million consist of 99.9% current assets and 0.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.8% |
| Accounts Receivable | $1.27 Million | 99.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.97K | 0.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2023)
This chart illustrates how Viaderma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Viaderma Inc's current assets represent 99.9% of total assets in 2023, an increase from 10.4% in 2007.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2023, down from 10.4% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 99.1% of total assets.
Viaderma Inc Competitors by Total Assets
Key competitors of Viaderma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Viaderma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Viaderma Inc generates 0.47x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Viaderma Inc generates $ 0.32 in net profit.
Viaderma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.97 | 0.96 | 0.42 |
| Quick Ratio | 0.43 | 0.96 | 0.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-146.22K | $ -49.54K | $ -535.17K |
Viaderma Inc - Advanced Valuation Insights
This section examines the relationship between Viaderma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 79.4% |
| Total Assets | $1.28 Million |
| Market Capitalization | $179.93 USD |
Valuation Analysis
Below Book Valuation: The market values Viaderma Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Viaderma Inc's assets grew by 79.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Viaderma Inc (2007–2023)
The table below shows the annual total assets of Viaderma Inc from 2007 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $1.28 Million | +79.39% |
| 2022-12-31 | $713.98K | +159.61% |
| 2021-12-31 | $275.02K | +123.53% |
| 2020-12-31 | $123.03K | +77.73% |
| 2019-12-31 | $69.22K | +22.71% |
| 2018-12-31 | $56.41K | -86.77% |
| 2017-12-31 | $426.56K | +10.36% |
| 2016-12-31 | $386.50K | +119.78% |
| 2015-12-31 | $175.86K | +1309.12% |
| 2014-12-31 | $12.48K | -99.97% |
| 2011-12-31 | $42.65 Million | +18.22% |
| 2010-12-31 | $36.07 Million | +20.05% |
| 2009-12-31 | $30.05 Million | +481538.71% |
| 2008-12-31 | $6.24K | -31.02% |
| 2007-12-31 | $9.04K | -- |